Verition Fund Management LLC Reduces Position in GH Research PLC (NASDAQ:GHRS)

Verition Fund Management LLC cut its stake in shares of GH Research PLC (NASDAQ:GHRS) by 7.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,057,782 shares of the company’s stock after selling 82,850 shares during the quarter. Verition Fund Management LLC owned about 2.03% of GH Research worth $7,077,000 as of its most recent SEC filing.

Separately, Lynx1 Capital Management LP lifted its position in GH Research by 19.8% during the 2nd quarter. Lynx1 Capital Management LP now owns 3,966,726 shares of the company’s stock worth $46,252,000 after acquiring an additional 656,163 shares during the period. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Stock Down 3.8 %

Shares of GHRS opened at $8.93 on Monday. The company has a market capitalization of $464.61 million, a price-to-earnings ratio of -11.30 and a beta of 0.74. GH Research PLC has a 52 week low of $5.05 and a 52 week high of $14.99. The stock’s 50-day moving average price is $8.04 and its 200-day moving average price is $10.18.

GH Research (NASDAQ:GHRS) last released its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.03. As a group, equities analysts anticipate that GH Research PLC will post -0.79 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on GHRS shares. Canaccord Genuity Group reduced their price objective on GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, November 18th. JMP Securities reissued a “market outperform” rating and set a $39.00 price target on shares of GH Research in a research report on Wednesday, September 4th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of GH Research in a report on Wednesday, November 20th.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).